Lupus
NICE says no to lupus treatment
September 30, 2011Sales and Marketing Benylsta, GSK, Lupus, NICE
NICE has rejected GSK’s new lupus treatment Benlysta in draft guidance.Co-developed with biotech company HGS, the drug has been hailed …
European recommendation for GSK’s lupus drug Benlysta
May 23, 2011Sales and Marketing Benlysta, CHMP, GlaxoSmithKline, Lupus
GlaxoSmithKline’s first-in-class lupus drug Benlysta has been given a major boost by regulators in the European Union. The European Medicines …
US approval for GSK’s lupus treatment Benlysta
March 10, 2011Sales and Marketing Benlysta, GSK, GlaxoSmithKline, Human Genome Sciences, Lupus, belimumab, systemic lupus erythematosus
GlaxoSmithKline’s lupus treatment Benylsta has won an historic approval in the US, but will have to prove its safety record …
UCB lupus candidate shows disease benefits
November 11, 2010Benlysta, Lupus, UCB, epratuzumab, monoclonal antibody, systemic lupus erythematosus
A new monoclonal antibody targeting the autoimmune disease lupus is continuing to show a positive effect on sufferers, its manufacturer …
Benlysta to be fast-tracked by FDA
August 20, 2010Sales and Marketing Benlysta, GSK, HGS, Lupus
New lupus drug Benlysta has been given priority review status by the FDA.Benlysta (belimumab) has been developed by Human Genome …
UCB’s new lupus treatment promising
June 17, 2010Research and Development Benlysta, Lupus, UCB, epratuzumab
A new monoclonal antibody treatment for lupus has shown promise in phase II trials, according to UCB. The biopharmaceutical company …
EU regulators to assess potential lupus breakthrough drug
June 8, 2010Sales and Marketing Benlysta, Human Genome Sciences, Lupus
GlaxoSmithKline and Human Genome Sciences have submitted a marketing application to the European Medicines Agency for their new lupus drug. …
Secondary endpoints failure take shine off Benlysta
April 21, 2010Sales and Marketing GSK, HGS, Lupus
GlaxoSmithKline’s lupus treatment has failed to reach a statistically significant secondary endpoint in the second of two phase III trials. …
Lupus drug shows surprise phase III success
July 23, 2009Research and Development, Sales and Marketing Benlysta, GSK, HGS, Lupus
GSK and Human Genome Sciences’ lupus drug Benlysta has surprised analysts by showing unexpectedly positive results in a pivotal late-stage …
Latest content
FibroFind appoints Lee Borthwick as CEO
